Trulicity Europäische Union - Französisch - EMA (European Medicines Agency)

trulicity

eli lilly nederland b.v. - dulaglutide - diabète sucré, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. pour les résultats de l'étude concernant les combinaisons, les effets sur le contrôle glycémique et d'événements cardiovasculaires, et les populations étudiées, voir les sections 4. 4, 4. 5 et 5.

Emgality Europäische Union - Französisch - EMA (European Medicines Agency)

emgality

eli lilly nederland b.v. - galcanezumab - troubles de la migraine - analgesics, galcanezumab - emgality est indiqué pour la prophylaxie de la migraine chez les adultes qui ont au moins 4 jours de migraine par mois.

Retsevmo Europäische Union - Französisch - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agents antinéoplasiques - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Baqsimi Europäische Union - Französisch - EMA (European Medicines Agency)

baqsimi

eli lilly nederland b.v. - le glucagon - diabète sucré - hormones pancréatiques, glycogenolytic hormones - baqsimi est indiqué pour le traitement de l'hypoglycémie sévère chez les adultes, les adolescents et les enfants âgés de 4 ans et plus atteints de diabète sucré.

Mounjaro Europäische Union - Französisch - EMA (European Medicines Agency)

mounjaro

eli lilly nederland b.v. - tirzepatide - diabète sucré, type 2 - les médicaments utilisés dans le diabète - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 et 5.

Jaypirca Europäische Union - Französisch - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lymphome, cellule du manteau - inhibiteurs de protéines kinases - treatment of mantle cell lymphoma (mcl).

Verzenios Europäische Union - Französisch - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - néoplasmes du sein - agents antinéoplasiques - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Rayvow Europäische Union - Französisch - EMA (European Medicines Agency)

rayvow

eli lilly nederland b.v. - lasmiditan succinate - troubles de la migraine - analgésiques - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Gemzar 200 mg Lyophilisat Schweiz - Französisch - Swissmedic (Swiss Agency for Therapeutic Products)

gemzar 200 mg lyophilisat

eli lilly (suisse) sa - gemcitabinum - lyophilisat - préparation cryodesiccata: gemcitabinum 200 mg à gemcitabini hydrochloridum, mannitolum, natrii acetas, pour le verre. - cytostaticum - synthetika

Gemzar 1 g Lyophilisat Schweiz - Französisch - Swissmedic (Swiss Agency for Therapeutic Products)

gemzar 1 g lyophilisat

eli lilly (suisse) sa - gemcitabinum - lyophilisat - préparation cryodesiccata: gemcitabinum 1 g de gemcitabini hydrochloridum, mannitolum, natrii acetas, pour le verre. - cytostaticum - synthetika